Breaking News

CureVac Appoints Dr. Malte Greune as COO

Dr. Florian von der Mülbe will shift focus exclusively toward the expansion and accelerated development of The RNA Printer.

Author Image

By: Charlie Sternberg

Associate Editor

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Dr. Malte Greune as chief operating officer (COO) effective July 1, 2021.   In this position, Greune will strengthen the company’s Management Board and will head, among others, CureVac’s clinical and commercial manufacturing activities. Greune joins CureVac with extensive experience in the global pharmaceutical industry, incl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters